However, CTCs undergoing epithelial–mesenchymal-transition (EMT) can gradually lose their epithelial characteristics, having no or very low expression of EpCAM and consequentially evade capture and increasingly CTC platforms are combining epithelial markers with others markers, such as mesenchymal markers (e.g., N-cadherin, vimentin or TWIST1), stem cell markers (CD133, CD44, CD34, ALDH1) (21) early apoptosis markers (M30, Bcl-2) or cancer specific markers (e.g., HER2, PSMA) (22, 23). The gene discussed is ERBB2; the disease is cancer.